AlivioTM Technology Platform

Our programs
Phase 1
Phase 2
Phase 3
AlivioTM Technology Platform
Phase completedPhase in progressRegistration-enabling studies planned
Pioneering inflammation targeted disease immunomodulation

Using our AlivioTM technology platform (includes undisclosed anti-inflammatory candidates), we are pioneering inflammation-targeted disease immunomodulation, which involves selectively restoring immune homeostasis at inflamed sites in the body, while having the potential for minimal impact on the rest of the body’s immune system, as a novel strategy to more effectively treat a range of chronic and acute inflammatory disorders. This long sought-after approach has the potential to broadly enable new medicines to treat a range of chronic and acute inflammatory disorders, including drugs which were previously limited by issues of systemic toxicity or pharmacokinetics (PK).

  • Key Points of Innovation & Differentiation
    • To achieve our vision of selective immunomodulation, we are advancing our Alivio technology platform centered on a class of self-assembling therapies that selectively bind to inflamed tissue. The platform is able to entrap a wide array of application programming interfaces (APIs) including small molecules, biologics and nucleic acids. By selectively targeting API pharmacology to inflamed tissue, our platform is designed to selectively treat autoimmune disease while avoiding the occurrence of potential systemic toxicities.
  • Program Discovery Process by the PureTech Team
    • A key challenge in new drug development for autoimmune and inflammatory disease is that attractive drug targets are frequently expressed in both diseased and normal tissue. Consequently, we were interested in identifying ways to address autoimmune disease in a targeted manner. We were inspired by the key observation that pathologic inflammation frequently manifests at specific sites in tissues and organs and is driven by dysfunctional immune signaling. Traditional approaches act broadly to suppress the immune system throughout the body which substantially limits the potential targets that can be pursued and frequently results in narrow therapeutic windows. Working with leading scientists, we identified and in-licensed a technology platform in May 2016 that was created by Jeffrey Karp, Ph.D., Professor of Medicine at Harvard Medical School and Brigham and Women’s Hospital, and Robert Langer, Sc.D., David H Koch Institute Professor at MIT. As demonstrated in multiple publications, our Alivio technology platform can be used to develop therapeutic candidates that selectively release drugs at inflamed sites of targeted tissues.
  • Patient Need & Market Potential
    • Preclinical results suggest our Alivio technology platform could be applied to diseases such as inflammatory bowel disease (IBD), inflammatory arthritis, organ transplantation and bladder pain syndrome (IC/BPS). These diseases collectively impact tens of millions of patients in the United States alone and have limited treatment options. IC/BPS is a chronic bladder condition that consists of discomfort or pain in the bladder or surrounding pelvic region and is often associated with frequent urination. It is estimated to affect four million to 12 million people in the United States. Current treatments fail to control pain in many patients. IBD is estimated to affect approximately three million people in the United States.
  • Milestones Achieved & Development Status
    • Using our Alivio technology platform, we have developed LYT-500 (see here), an oral combination therapy in development for IBD, LYT-503/IMB-150 (see here), our therapeutic candidate being advanced in collaboration with Imbrium Therapeutics for the potential treatment of interstitial cystitis, or IC/BPS.
    • In October 2020, we announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance a second potential therapeutic option for the treatment of IBD through our anti-inflammatory programs. The funds will support preclinical research and development activities.
  • Expected Milestones
    • We expect preclinical proof-of-concept data for LYT-500 (see here) in 2022.
    • An IND filing for LYT-503/IMB-150 (see here) for IC/BPS is expected in 2021.
    • We are evaluating the potential application of our Alivio technology platform in additional indications through our anti-inflammatory programs.
  • Intellectual Property
    • Intellection property portfolio covering the Alivio inflammation-targeting technology platform consists of six patent families. Collectively, across these patent families, there are eight issued and/or allowed U.S. or international patents to date with claims covering inflammation-targeting compositions, methods of making, and methods of using as drug products. Additionally, there are several patent applications within each family that are pending in the U.S. and/or internationally to provide additional protection. All patents and patent applications covering the technology platform have been obtained from the Brigham and Women’s Hospital under an exclusive licensing agreement in all territories.

Our Alivio technology platform has been described in five peer-reviewed articles published in journals such as Science Translational Medicine and Nature Communications, and has been validated in multiple labs using preclinical models for a range of different indications.